Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Ifosfamide"" wg kryterium: Temat


Tytuł :
Ifosfamide induced encephalopathy in a child with osteosarcoma.
Autorzy :
Sarbay H; Faculty of Medicine, Pediatric Hematology and Oncology, Bone Marrow Transplantation Unit, TC Istanbul Yeni Yuzyil University, Istanbul, Turkey.
Demir ÜF; Faculty of Medicine, Neurology, TC Istanbul Yeni Yuzyil University, Istanbul, Turkey.
Yılmaz G; Faculty of Medicine, Radiology, TC Istanbul Yeni Yuzyil University, Istanbul, Turkey.
Atay AA; Faculty of Medicine, Pediatric Hematology and Oncology, Bone Marrow Transplantation Unit, TC Istanbul Yeni Yuzyil University, Istanbul, Turkey.
Malbora B; Faculty of Medicine, Pediatric Hematology and Oncology, Bone Marrow Transplantation Unit, TC Istanbul Yeni Yuzyil University, Istanbul, Turkey.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2021 Jul; Vol. 27 (5), pp. 1302-1306. Date of Electronic Publication: 2020 Oct 06.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antineoplastic Agents, Alkylating/*adverse effects
Brain Diseases/*chemically induced
Ifosfamide/*adverse effects
Adolescent ; Antineoplastic Agents, Alkylating/administration & dosage ; Bone Neoplasms/drug therapy ; Female ; Humans ; Ifosfamide/administration & dosage ; Methylene Blue/administration & dosage ; Neurotoxicity Syndromes/etiology ; Osteosarcoma/drug therapy
Czasopismo naukowe
Tytuł :
An in vitro cytotoxicity of glufosfamide in HepG2 cells relative to its nonconjugated counterpart.
Autorzy :
Ahmed DE; Department of Biochemistry, Misr University for Science & Technology (MUST), Giza, Egypt.
Rashidi FB; Biochemistry Lab.Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt. .
Abdelhakim HK; Biochemistry Lab.Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt.
Mohamed AS; Biochemistry Lab.Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt.
Arafa HMM; Department of Pharmacology and Toxicology, Faculty of Pharmacy Ahram Canadian University, Giza, 267119, Egypt.
Pokaż więcej
Źródło :
Journal of the Egyptian National Cancer Institute [J Egypt Natl Canc Inst] 2021 Aug 23; Vol. 33 (1), pp. 22. Date of Electronic Publication: 2021 Aug 23.
Typ publikacji :
Journal Article
MeSH Terms :
Ifosfamide*/analogs & derivatives
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Glucose/analogs & derivatives ; Hep G2 Cells ; Humans
Czasopismo naukowe
Tytuł :
Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or naturalkiller/T-cell lymphoma.
Autorzy :
Tang T; Division of Medical Oncology, National Cancer Centre Singapore. .
Martin P; Division of Medicine, Weill Cornell Medical College, New York.
Somasundaram N; Division of Medical Oncology, National Cancer Centre Singapore.
Lim C; Division of Clinical Trials and Epidemiology, National Cancer Centre Singapore.
Tao M; Division of Medical Oncology, National Cancer Centre Singapore.
Poon E; Division of Medical Oncology, National Cancer Centre Singapore.
Yunon MJ; Division of Clinical Trials and Epidemiology, National Cancer Centre Singapore.
Toh SQ; Division of Clinical Trials and Epidemiology, National Cancer Centre Singapore.
Yan SX; Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital.
Farid M; Division of Medical Oncology, National Cancer Centre Singapore.
Chan JY; Division of Medical Oncology, National Cancer Centre Singapore.
Lim ST; Division of Medical Oncology, National Cancer Centre Singapore.
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2020 Nov 05; Vol. Online ahead of print. Date of Electronic Publication: 2020 Nov 05.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Ifosfamide*/adverse effects
Lymphoma, T-Cell*
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/adverse effects ; Dexamethasone ; Etoposide/adverse effects ; Humans ; Hydrazines ; Neoplasm Recurrence, Local ; Triazoles
Czasopismo naukowe
Tytuł :
A Case of Retroperitoneal Synovial Sarcoma in Pregnancy Treated with Antepartum Doxorubicin plus Ifosfamide Chemotherapy.
Autorzy :
Sipe, Bradley H. (AUTHOR)
Običan, Sarah G. (AUTHOR)
Henderson-Jackson, Evita (AUTHOR)
Riddle, Nicole D. (AUTHOR)
Makanji, Rikesh (AUTHOR)
Gonzalez, Ricardo J. (AUTHOR)
Brohl, Andrew S. (AUTHOR)
Pokaż więcej
Źródło :
Case Reports in Oncological Medicine. 7/19/2021, p1-8. 8p.
Czasopismo naukowe
Tytuł :
Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis.
Autorzy :
Saito S; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Aiba H; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. .
Yamada S; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Okamoto H; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Hayashi K; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.; Department of Orthopedic Surgery, Kanazawa University Graduate School of Medical Science, 13-1, Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Kimura H; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.; Department of Orthopedic Surgery, Kanazawa University Graduate School of Medical Science, 13-1, Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Miwa S; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.; Department of Orthopedic Surgery, Kanazawa University Graduate School of Medical Science, 13-1, Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Otsuka T; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.; Department of Education, Tokai Gakuen University, 2-901, Nakadaira, Tenpaku-ku, Nagoya, Aichi, 468-0014, Japan.
Murakami H; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2020 Sep 09; Vol. 20 (1), pp. 868. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji :
Journal Article
MeSH Terms :
Doxorubicin/*analogs & derivatives
Etoposide/*administration & dosage
Ifosfamide/*administration & dosage
Sarcoma/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Drug-Related Side Effects and Adverse Reactions/classification ; Drug-Related Side Effects and Adverse Reactions/pathology ; Etoposide/adverse effects ; Female ; Humans ; Ifosfamide/adverse effects ; Leukopenia/chemically induced ; Leukopenia/pathology ; Male ; Middle Aged ; Sarcoma/pathology ; Thrombocytopenia/chemically induced ; Thrombocytopenia/pathology
Czasopismo naukowe
Tytuł :
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
Autorzy :
Gaspar N; Department of Childhood and Adolescent Oncology, Gustave Roussy Cancer Centre, Villejuif, France. Electronic address: .
Venkatramani R; Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Hecker-Nolting S; Klinikum Stuttgart, Olga Hospital, Stuttgart, Germany.
Melcon SG; Vall d'Hebron University Hospital, Barcelona, Spain.
Locatelli F; Ospedale Pediatrico Bambino Gesù, Sapienza University of Rome, Rome, Italy.
Bautista F; Hospital Infantil Universitario Niño Jesus, Madrid, Spain.
Longhi A; IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Lervat C; Pediatric and AYA Oncology Unit, Centre Oscar Lambret, Lille, France.
Entz-Werle N; Chu Strasbourg-Hôpital Hautepierre, Strasbourg, France.
Casanova M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Aerts I; SIREDO Oncology Center, PSL Research University, Institut Curie, Paris, France.
Strauss SJ; University College London Hospital, London, UK.
Thebaud E; CHU Nantes-Hôpital Mère-Enfant, Nantes, France.
Morland B; Birmingham Children's Hospital, Birmingham, UK.
Nieto AC; Hospital Universitario y Politecnico La Fe, Valencia, Spain.
Marec-Berard P; Centre Léon Bérard, Lyon, France.
Gambart M; CHU de Toulouse, Hôpital des Enfants, Toulouse, France.
Rossig C; Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.
Okpara CE; Eisai, Hatfield, UK.
He C; Eisai, Woodcliff Lake, NJ, USA.
Dutta L; Eisai, Woodcliff Lake, NJ, USA.
Campbell-Hewson Q; The Great North Children's Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, UK.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Sep; Vol. 22 (9), pp. 1312-1321. Date of Electronic Publication: 2021 Aug 17.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bone Neoplasms/*drug therapy
Osteosarcoma/*drug therapy
Phenylurea Compounds/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Quinolines/*therapeutic use
Adolescent ; Adult ; Bone Neoplasms/pathology ; Child ; Child, Preschool ; Cohort Studies ; Drug Resistance, Neoplasm ; Drug-Related Side Effects and Adverse Reactions ; Etoposide/therapeutic use ; Female ; Humans ; Ifosfamide/therapeutic use ; Male ; Neoplasm Recurrence, Local ; Osteosarcoma/pathology ; Progression-Free Survival ; Response Evaluation Criteria in Solid Tumors ; Young Adult
Czasopismo naukowe
Tytuł :
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Autorzy :
Lynch RC; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Cassaday RD; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Smith SD; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Fromm JR; Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.
Cowan AJ; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Warren EH; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Shadman MS; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Shustov A; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Till BG; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ujjani CS; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Libby EN 3rd; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Philip M; Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Coye H; Seattle Cancer Care Alliance, Seattle, WA, USA.
Martino CN; Seattle Cancer Care Alliance, Seattle, WA, USA.
Bhark SL; Seattle Cancer Care Alliance, Seattle, WA, USA.
Morris K; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
Rasmussen H; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
Behnia S; Department of Radiology, University of Washington, Seattle, WA, USA.
Voutsinas J; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gopal AK; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2021 Aug; Vol. 8 (8), pp. e562-e571.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
MeSH Terms :
Salvage Therapy*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Drug Resistance, Neoplasm/*drug effects
Hodgkin Disease/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Adult ; Brentuximab Vedotin/administration & dosage ; Carboplatin/administration & dosage ; Etoposide/administration & dosage ; Female ; Follow-Up Studies ; Hodgkin Disease/pathology ; Humans ; Ifosfamide/administration & dosage ; Male ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Survival Rate
Czasopismo naukowe
Tytuł :
Sequencing therapies in Hodgkin lymphoma.
Autorzy :
Phillips EH; University of Manchester, The Christie Hospital and National Institutes of Health Research Manchester Biomedical Research Centre, Manchester M20 4BX, UK. Electronic address: .
Collins GP; Department of Clinical Haematology, Oxford University Hospitals, Oxford, UK.
Cwynarski K; Department of Haematology, University College Hospital London, London, UK.
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2021 Aug; Vol. 8 (8), pp. e537-e539.
Typ publikacji :
Journal Article
MeSH Terms :
Hodgkin Disease/*therapy
Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bleomycin/therapeutic use ; Brentuximab Vedotin/therapeutic use ; Carboplatin/therapeutic use ; Dacarbazine/therapeutic use ; Disease Management ; Doxorubicin/therapeutic use ; Etoposide/therapeutic use ; Hematopoietic Stem Cell Transplantation ; Humans ; Ifosfamide/therapeutic use ; Vinblastine/therapeutic use
SCR Protocol :
ABVD protocol
Czasopismo naukowe
Tytuł :
Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Autorzy :
Ferrari A; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy. Electronic address: .
van Noesel MM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Division Cancer and Imaging, University Medical Center Utrecht, Utrecht, Netherlands.
Brennan B; Paediatric Oncology, Royal Manchester Children's Hospital, Manchester, UK.
Zanetti I; Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padova, Italy.
Corradini N; Department of Pediatric Oncology, Institut d'Hematologie et d'Oncologie Pédiatrique/Centre Léon Bérard, Lyon, France.
Casanova M; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
Berlanga P; Department of Pediatric and Adolescent Oncology, Gustave-Roussy, Cancer Campus, Université Paris-Saclay, Villejuif, France.
Merks JHM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands.
Alaggio R; Pathology Department, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy.
Schifflers S; Department of Pediatrics, Clinique CHC MontLégia, Liège, Belgium.
Ramirez-Villar GL; Pediatric Oncology Unit, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Giraudo C; Department of Medicine DIMED, University of Padova, Padova, Italy.
Burrieza GG; Surgical Oncology and Neonatal Surgery, Pediatric Surgery Department, Hospital Infantil Universitari Vall d'Hebron, Barcelona, Spain.
Safwat A; Oncology Department and Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
Bisogno G; Hematology Oncology Division, Department of Women's and Children's Health, University of Padova, Padova, Italy.
De Salvo GL; Clinical Research Unit, IRCCS Istituto Oncologico Veneto, Padova, Italy.
Orbach D; SIREDO Oncology Center, Institut Curie, PSL University, Paris, France.
Pokaż więcej
Źródło :
The Lancet. Child & adolescent health [Lancet Child Adolesc Health] 2021 Aug; Vol. 5 (8), pp. 546-558. Date of Electronic Publication: 2021 Jun 30.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Sarcoma*/drug therapy
Sarcoma*/radiotherapy
Sarcoma*/surgery
Soft Tissue Neoplasms*/drug therapy
Soft Tissue Neoplasms*/radiotherapy
Soft Tissue Neoplasms*/surgery
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Doxorubicin/*administration & dosage
Ifosfamide/*administration & dosage
Adolescent ; Chemoradiotherapy, Adjuvant ; Child ; Disease-Free Survival ; Europe ; Female ; Humans ; Male ; Neoplasm Staging ; Practice Guidelines as Topic/standards ; Prospective Studies ; Sarcoma, Synovial/drug therapy ; Sarcoma, Synovial/radiotherapy ; Sarcoma, Synovial/surgery
Czasopismo naukowe
Tytuł :
What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?
Autorzy :
Hindi N; Oncology Department, Fundacion Jimenez Diaz University Hospital, Av Reyes Catolicos 2, 28040 Madrid (Spain)/Villalba University Hospital/Rey Juan Carlos I University Hospital/Infanta Elena University Hospital and Research Institute FJD-UAM, Madrid (Spain) and ATBsarc, CITIUS III, Seville, Spain.
Martin-Broto J
Pokaż więcej
Źródło :
Current opinion in oncology [Curr Opin Oncol] 2021 Jul 01; Vol. 33 (4), pp. 329-335.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Sarcoma/*drug therapy
Sarcoma/*surgery
Soft Tissue Neoplasms/*drug therapy
Soft Tissue Neoplasms/*surgery
Anthracyclines/administration & dosage ; Chemotherapy, Adjuvant ; Clinical Trials, Phase II as Topic ; Extremities/pathology ; Humans ; Ifosfamide/administration & dosage ; Neoadjuvant Therapy ; Randomized Controlled Trials as Topic ; Retroperitoneal Neoplasms/drug therapy
Czasopismo naukowe
Tytuł :
IAP Chemotherapy Regimen Is a Viable and Cost-effective Option in Children and Adolescents With Osteosarcoma: A Comparative Analysis With MAP Regimen on Toxicity and Survival.
Autorzy :
Verma P; Departments of Pediatric Hematology and Oncology.
Jain S; Departments of Pediatric Hematology and Oncology.
Kapoor G; Departments of Pediatric Hematology and Oncology.
Tripathi R; Research.
Sharma P; Departments of Pediatric Hematology and Oncology.
Doval DC; Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, Delhi, India.
Pokaż więcej
Źródło :
Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2021 May 01; Vol. 43 (4), pp. e466-e471.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bone Neoplasms/*drug therapy
Methotrexate/*therapeutic use
Osteosarcoma/*drug therapy
Adolescent ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/economics ; Bone Neoplasms/economics ; Child ; Cisplatin/adverse effects ; Cisplatin/economics ; Cisplatin/therapeutic use ; Cost-Benefit Analysis ; Disease-Free Survival ; Doxorubicin/adverse effects ; Doxorubicin/economics ; Doxorubicin/therapeutic use ; Female ; Humans ; Ifosfamide/adverse effects ; Ifosfamide/economics ; Ifosfamide/therapeutic use ; Male ; Methotrexate/adverse effects ; Methotrexate/economics ; Osteosarcoma/economics ; Retrospective Studies ; Salvage Therapy/economics
SCR Protocol :
IAP protocol
Czasopismo naukowe
Tytuł :
Probing prodrug metabolism and reciprocal toxicity with an integrated and humanized multi-tissue organ-on-a-chip platform.
Autorzy :
Rajan SAP; Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA; Virginia Tech -Wake Forest School of Biomedical Engineering and Sciences, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Aleman J; Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Wan M; Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Pourhabibi Zarandi N; Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Nzou G; Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Murphy S; Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Bishop CE; Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Sadri-Ardekani H; Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Shupe T; Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Atala A; Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Hall AR; Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA; Virginia Tech -Wake Forest School of Biomedical Engineering and Sciences, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest Baptist, Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. Electronic address: .
Skardal A; Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA; Virginia Tech -Wake Forest School of Biomedical Engineering and Sciences, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest Baptist, Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157; Department of Biomedical Engineering, The Ohio State University, 1080 Carmack Rd., Columbus, OH 43210; The Ohio State University Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, 460 W 10th Ave, Columbus, OH 43210. Electronic address: .
Pokaż więcej
Źródło :
Acta biomaterialia [Acta Biomater] 2020 Apr 01; Vol. 106, pp. 124-135. Date of Electronic Publication: 2020 Feb 14.
Typ publikacji :
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Lab-On-A-Chip Devices*
Capecitabine/*metabolism
Ifosfamide/*metabolism
Microfluidic Analytical Techniques/*methods
Organoids/*metabolism
Prodrugs/*metabolism
Capecitabine/toxicity ; Cell Culture Techniques ; Cell Line, Tumor ; Human Umbilical Vein Endothelial Cells ; Humans ; Hyaluronic Acid/chemistry ; Hydrogels/chemistry ; Ifosfamide/toxicity ; Organoids/drug effects ; Prodrugs/toxicity
Czasopismo naukowe
Tytuł :
Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy.
Autorzy :
Lentz KL; Barnes-Jewish Hospital, Saint Louis, MO, USA.
Clark SM; University of North Carolina Medical Center, Chapel Hill, NC, USA.
Ayarza M; University of North Carolina Medical Center, Chapel Hill, NC, USA.
Liu B; Department of Biostatistics & Bioinformatics, Duke University, Durham, NC, USA.
Morgan KP; University of North Carolina Medical Center, Chapel Hill, NC, USA.
Wind LS; University of North Carolina Medical Center, Chapel Hill, NC, USA.
Hairston A; Durham Veterans Affairs Medical Center, Durham, NC, USA.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2020 Mar; Vol. 26 (2), pp. 406-412. Date of Electronic Publication: 2019 Jul 09.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Brain Diseases/*prevention & control
Ifosfamide/*adverse effects
Thiamine/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Brain Diseases/chemically induced ; Carboplatin/administration & dosage ; Cohort Studies ; Etoposide/administration & dosage ; Female ; Humans ; Ifosfamide/administration & dosage ; Incidence ; Lymphoma/drug therapy ; Male ; Middle Aged ; Neurotoxicity Syndromes/etiology ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Less nephrotoxicity of paclitaxel and ifosfamide plus nedaplatin for refractory or relapsed germ cell tumors in patients with impaired renal function.
Autorzy :
Shiraishi T; Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Nakamura T; Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.; Department of Urology, Saiseikai Imperial Gift Foundation, Saiseikai Suita Hospital, Osaka, Japan.
Takamura T; Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Oishi M; Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yamada T; Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yamada Y; Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Ueda T; Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Fujihara A; Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hongo F; Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Okihara K; Department of Urology, North Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Ukimura O; Department of Urology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Pokaż więcej
Źródło :
International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2020 Feb; Vol. 27 (2), pp. 134-139. Date of Electronic Publication: 2019 Nov 07.
Typ publikacji :
Journal Article
MeSH Terms :
Ifosfamide*/adverse effects
Neoplasms, Germ Cell and Embryonal*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cisplatin ; Humans ; Organoplatinum Compounds ; Paclitaxel/adverse effects ; Salvage Therapy ; Treatment Outcome
Czasopismo naukowe
Tytuł :
R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - Long term follow up results.
Autorzy :
Alderuccio JP; Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Saul EE; Department of Medicine, Division of Internal Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Iyer SG; Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Reis IM; Department of Public Health Science, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.; Sylvester Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Alencar AJ; Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Rosenblatt JD; Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Lossos IS; Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.; Department of Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 Jun 01; Vol. 96 (6), pp. 680-689. Date of Electronic Publication: 2021 Apr 07.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Mantle-Cell/*drug therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/administration & dosage ; Cytarabine/administration & dosage ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Etoposide/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Ifosfamide/administration & dosage ; Kaplan-Meier Estimate ; Maintenance Chemotherapy ; Male ; Methotrexate/administration & dosage ; Middle Aged ; Progression-Free Survival ; Prospective Studies ; Remission Induction ; Rituximab/administration & dosage ; Thalidomide/administration & dosage ; Thalidomide/toxicity ; Vincristine/administration & dosage ; Young Adult
SCR Protocol :
IVAM regimen
Czasopismo naukowe
Tytuł :
Modern multimodality management of patients with caval leiomyosarcoma: New treatment paradigms and potential molecular insights.
Autorzy :
Squires MH; Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.
Politano S; Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, Ohio, USA.
Pollock RE; Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, Ohio, USA.
Chen JL; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.; Division of Bioinformatics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio, USA.
Grignol V; Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, Ohio, USA.
Pokaż więcej
Źródło :
Journal of surgical oncology [J Surg Oncol] 2021 Jun; Vol. 123 (7), pp. 1618-1623. Date of Electronic Publication: 2021 Mar 02.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leiomyosarcoma/*drug therapy
Leiomyosarcoma/*surgery
Retroperitoneal Neoplasms/*drug therapy
Retroperitoneal Neoplasms/*surgery
Vascular Neoplasms/*drug therapy
Vascular Neoplasms/*surgery
Vena Cava, Inferior/*pathology
Antibodies, Monoclonal/administration & dosage ; Cohort Studies ; Dacarbazine/administration & dosage ; Doxorubicin/administration & dosage ; Female ; Humans ; Ifosfamide/administration & dosage ; Leiomyosarcoma/genetics ; Leiomyosarcoma/pathology ; Male ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Retroperitoneal Neoplasms/genetics ; Retroperitoneal Neoplasms/pathology ; Retrospective Studies ; Vascular Neoplasms/genetics ; Vascular Neoplasms/pathology ; Vena Cava, Inferior/surgery
Czasopismo naukowe
Tytuł :
Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold.
Autorzy :
Xiong C; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; Pharm-X Center, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Zhou L; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Tan J; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; Pharm-X Center, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Song S; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Bao X; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Zhang N; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Ding H; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Zhao J; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; Pharm-X Center, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
He JX; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Miao ZH; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Zhang A; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China.; Pharm-X Center, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.; University of Chinese Academy of Sciences, Beijing 100049, China.; Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.; State Key Laboratory of Esophageal Cancer Prevention and Treatment, Ministry of Education of China, Zhengzhou University, Zhengzhou 450001, China.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2021 May 13; Vol. 64 (9), pp. 6161-6178. Date of Electronic Publication: 2021 Apr 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Design*
Enzyme Inhibitors/*chemistry
Enzyme Inhibitors/*pharmacology
Tirapazamine/*chemistry
Tirapazamine/*pharmacology
Ubiquitin-Activating Enzymes/*antagonists & inhibitors
Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Antineoplastic Combined Chemotherapy Protocols ; Cell Line, Tumor ; Cisplatin ; Enzyme Inhibitors/pharmacokinetics ; Humans ; Ifosfamide ; Mitomycin ; Tirapazamine/pharmacokinetics ; Tissue Distribution ; Xenograft Model Antitumor Assays
SCR Protocol :
MIP protocol
Czasopismo naukowe
Tytuł :
Immunotherapy for osteosarcoma.
Autorzy :
Yahiro K; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Matsumoto Y; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Pokaż więcej
Źródło :
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2021 May 04; Vol. 17 (5), pp. 1294-1295. Date of Electronic Publication: 2020 Dec 24.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*
Osteosarcoma*/drug therapy
Child ; Cisplatin/therapeutic use ; Humans ; Ifosfamide/therapeutic use ; Immunotherapy ; Neoplasm Recurrence, Local
Czasopismo naukowe
Tytuł :
Para-neoplastic optic neuritis presenting in a child with fusion positive localised para-testicular alveolar rhabdomyosarcoma.
Autorzy :
Gordon K; Department of Pediatrics, Royal Aberdeen Children's Hospital, Aberdeen, UK.
Ahmad N; Department of Pediatrics, Royal Aberdeen Children's Hospital, Aberdeen, UK.; Department of Pediatric Hematology & Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Pokaż więcej
Źródło :
Pediatric hematology and oncology [Pediatr Hematol Oncol] 2021 May; Vol. 38 (4), pp. 397-402. Date of Electronic Publication: 2020 Oct 23.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Blindness/*etiology
Optic Neuritis/*complications
Rhabdomyosarcoma/*complications
Testicular Neoplasms/*complications
Adolescent ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Blindness/pathology ; Blindness/therapy ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Etoposide/therapeutic use ; Humans ; Ifosfamide/therapeutic use ; Immunoglobulins/therapeutic use ; Male ; Optic Neuritis/pathology ; Optic Neuritis/therapy ; Rhabdomyosarcoma/pathology ; Rhabdomyosarcoma/therapy ; Steroids/therapeutic use ; Testicular Neoplasms/pathology ; Testicular Neoplasms/therapy ; Vincristine/therapeutic use
SCR Protocol :
IVAD protocol
Raport
Tytuł :
MTSS1 inhibits colorectal cancer metastasis by regulating the CXCR4/CXCL12 signaling axis.
Autorzy :
Chen L; Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China.
Chen Q; Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China.
Wu Y; Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China.
Zhu M; Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China.
Hu J; Department of Genetics and Bioinformatics, College of Basic Medicine and Biological Sciences of Soochow University, Suzhou, Jiangsu 215004, P.R. China.
Zhuang Z; Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China.
Pokaż więcej
Źródło :
International journal of molecular medicine [Int J Mol Med] 2021 May; Vol. 47 (5). Date of Electronic Publication: 2021 Mar 02.
Typ publikacji :
Journal Article
MeSH Terms :
Signal Transduction*
Chemokine CXCL12/*metabolism
Colorectal Neoplasms/*metabolism
Microfilament Proteins/*metabolism
Neoplasm Proteins/*metabolism
Receptors, CXCR4/*metabolism
Animals ; Antineoplastic Combined Chemotherapy Protocols ; Chemokine CXCL12/genetics ; Cisplatin ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; HT29 Cells ; Humans ; Ifosfamide ; Male ; Mice, Inbred BALB C ; Mice, Nude ; Microfilament Proteins/genetics ; Mitomycin ; Neoplasm Metastasis ; Neoplasm Proteins/genetics ; Receptors, CXCR4/genetics
SCR Protocol :
MIP protocol
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies